PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review.

Cancers (Basel) · 2019 · PMC6679223 · PMID 31336685

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

These results looked similar to those previously reported for cobimetinib plus paclitaxel without atezolizumab, but there was a numerical trend for a higher response rate in subgroups with PD-L1-positive tumor-infiltrating immune cells.

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.